Research programme: gene therapies - Genethon/ViroMed

Drug Profile

Research programme: gene therapies - Genethon/ViroMed

Alternative Names: AAV vector containing modified U7 snRNA gene for Duchenne muscular dystrophy - Genethon; AAV vector transferred UGT1A1 gene - Genethon; Gene therapy for Crigler-Najjar syndrome - Genethon; Gene therapy for Duchenne muscular dystrophy - Genethon; Gene therapy for Leber's hereditary optic neuropathy (LHON) - Genethon; Gene therapy for myotubular myopathy - Genethon/Wake Forest University School of Medicine; SMN1 gene therapy for spinal muscular atrophy - Genethon; VM 101 - ViroMed; VM 102; VM 103; VM 104; VM 105

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Genethon; ViroMed; Wake Forest University School of Medicine
  • Class Gene therapies
  • Mechanism of Action Dystrophin expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • No development reported Congenital structural myopathies; Duchenne muscular dystrophy; Eye disorders; Immunological disorders; Liver disorders; Metabolic disorders; Musculoskeletal disorders; Spinal muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Congenital structural myopathies in France (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Congenital structural myopathies in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top